sevelamer – kdc

CLINICAL USE

Phosphate-binding agent

DOSE IN NORMAL RENAL FUNCTION

1–5 tablets (average: 3–5) 3 times a day with meals; adjust according to serum phosphate level

PHARMACOKINETICS

Molecular weight :Large

%Protein binding :No data

%Excreted unchanged in urine : No data

Volume of distribution (L/kg) :No data

half-life – normal/ESRD (hrs) :No data

DOSE IN RENAL IMPAIRMENT

GFR (mL/MIN)

20 to 50 : Dose as in normal renal function

10 to 20 : Dose as in normal renal function

<10 : Dose as in normal renal function

DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

CAPD :Unlikely to be dialysed. Dose as in normal renal function

HD :Unlikely to be dialysed. Dose as in normal renal function

HDF/high flux :Unlikely to be dialysed. Dose as in normal renal function

CAV/VVHD :Unlikely to be dialysed. Dose as in normal renal function

IMPORTANT DRUG INTERACTIONS

Potentially hazardous interactions with other drugsMycophenolate: may reduce mycophenolate levels

ADMINISTRATION

Reconstition

–

Route

Oral

Rate of Administration

–

Comments

–

OTHER INFORMATION

Do not use if the patient has swallowing disorders or untreated or severe gastroparesisRenagel is not systemically absorbed One tablet = 800 mg of poly(allylamine hydrochloride) polymerCan be dispersed in 10 mL sodium bicarbonate 8.4% injection if patient is unable to take the tablets.

Tags: post-by-auto-php